Senti Biosciences Completes Merger With Up to $60 Million in Milestone Payments
Senti Biosciences completed its merger and arranged contingent value rights tied to SENTI-202, with potential payments of up to $60 million based on regulatory and sales milestones. It also acquired intellectual property and research assets for its Rett Syndrome and TIL programs.